Drugs / Autologous dual-target CAR-T cells selected from the predefined target library.
Autologous dual-target CAR-T cells selected from the predefined target library.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07523529 | Mar 2026 → Apr 2027 expected | metastatic malignant neoplasm | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous dual-target CAR-T cells selected from the predefined target library. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523529 ↗ |
| Action | Deplete | “administered to enhance tumor targeting and reduce antigen escape” NCT07523529 ↗ |
| Modality | Cell therapy | “Autologous dual-target CAR-T cells are patient-derived T cells engineered to recognize two tumor-associated antigens selected from a predefined target library.” NCT07523529 ↗ |